0
variable(s) selected download| Category | Variable name | variable label (+ explanatory notes) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient data | gebdat | Date of birth | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patient data | gesl | Sex |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patient data | iacr | Counts following IACR rules for reporting incidence |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patient data | incdat | Incidence date
+
The incidence date is the date of the first histological or cytological confirmation of the tumour. It cannot be later than the start of treatment. If treatment begins before histological confirmation, the incidence date is the date of clinical diagnosis. It must always fall within three months of the first clinical visit related to this tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patient data | incjr | Year of incidence
+
The incidence date is the date of the first histological or cytological confirmation of the tumour. It cannot be later than the start of treatment. If treatment begins before histological confirmation, the incidence date is the date of clinical diagnosis. It must always fall within three months of the first clinical visit related to this tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patient data | ink_ses | Median income in postal code area as a proxy for socioeconomic status (SES)
+
Available from 2010. Socioeconomic status (SES) reflects an individual's social position, which strongly influences health and is linked to life expectancy in good health. Research on SES and health typically uses indicators such as education, income, occupation, and material wealth. This variable uses income as a proxy for SES.
Income data by postal code area were obtained from Statistics Netherlands (CBS), with 2019 as the reference year, downloaded on 16 October 2023 via https://www.cbs.nl/nl-nl/dossier/nederland-regionaal/geografische-data
/gegevens-per-postcode.
Income is defined as the median disposable household income, adjusted for household size and composition. For each area, the median standardised household income was compared to the national distribution and classified into one of five groups: low, lower-middle, middle, upper-middle, or high. Income thresholds (in euros) are available at: https://www.cbs.nl/nl-nl/longread/diversen/2023/statistische-gegevens-per-vierkant-en-postcode-2022-2021-2020-2019/4-beschrijving-cijfers. Because postal code areas often have few households, CBS also
considered the 99% confidence interval of the median income. If this interval spans multiple groups, a new category was created to reflect the range (e.g., 'low to lower-middle'). Categories may partially overlap due to this approach. If the median income is based on fewer than 10 households, it is classified as 'unclassifiable'. CBS originally defined 12 income categories.
For this variable, these were reduced to three to simplify analysis and remove overlaps.
Key considerations:
- Income is a snapshot and does not reflect accumulated wealth.
- Data are aggregated by postal code area, which may include substantial variation.
- Household income is strongly age-dependent; analyses should compare individuals within the same age group.
- Median disposable income is considered valid for up to 10 years before and after the reference year (2019).
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patient data | leeft | Age at incidence date | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patient data | mal | Previous or subsequent malignancies
+
Selection of malignancies to specify in the request:
-Period: Previous and/or subsequent malignancies, or based on a defined timeframe before or around the incidence date.
-Type: All cancer types in the NCR, or all malignant/invasive (excluding skin BCC), or a selection of specific tumour types.
NKR database content with full availability:
Period: Nationwide complete from 1989.
Exclusion criteria:
- Patients residing abroad at the time of incidence
- Basal cell carcinomas of skin and lip
- Second primary invasive and second non-invasive squamous cell carcinomas of the skin
- Adenocarcinoma in situ/high-grade dysplasia of colon, rectosigmoid and rectum
- Carcinoma in situ of the cervix
- Benign/borderline tumours, except: CNS tumours from 2001, Borderline ovarian tumours, AL amyloidosis from 2017, Polymorphic PTLD
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patient data | mal_incdat | Incidence date of previous or subsequent malignancy | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patient data | mal_int | Interval between incidence date and date of previous or subsequent malignancy | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patient data | mal_tumsoort | Tumour type of previous or subsequent malignancy
+
Refers to the NCR tumour classification based on site, morphology, and behaviour. For more information, see: https://iknl.nl/nkr/registratie/tumorindeling
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patient data | ovldat | Date of death | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patient data | post_cijf | Numeric part of the patient's postal code at the time of incidence | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patient data | vit_stat_dat | Date of vital status
+
Once a year, at the end of the first quarter, the NCR is linked to the Municipal Personal Records Database (GBA). The GBA is complete up to February of that year. Vital status reflects the status up to this date. For patients listed as alive in the GBA, the vital status date is the date up to which the GBA is complete. If a patient is recorded as deceased or emigrated, the vital status date is the date of death or emigration. Using this date and the incidence date, the interval between incidence and vital status (in days) is calculated.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patient data | vit_stat_int | Interval between incidence date and date of vital status (days)
+
Once a year, at the end of the first quarter, the NCR is linked to the Municipal Personal Records Database (GBA). The GBA is complete up to February of that year. Vital status reflects the status up to this date. For patients listed as alive in the GBA, the vital status date is the date up to which the GBA is complete. If a patient is recorded as deceased or emigrated, the vital status date is the date of death or emigration. Using this date and the incidence date, the interval between incidence and vital status (in days) is calculated.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patient data | vit_stat | Vital status
+
Once a year, at the end of the first quarter, the NCR is linked to the Municipal Personal Records Database (GBA). The GBA is complete up to February of that year. Vital status reflects the status up to this date. For patients listed as alive in the GBA, the vital status date is the date up to which the GBA is complete. If a patient is recorded as deceased or emigrated, the vital status date is the date of death or emigration. Using this date and the incidence date, the interval between incidence and vital status (in days) is calculated.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | topo | Topography excluding sublocation
+
Location of the primary tumour according to ICD-O-3.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | topo_sublok | Topography including sublocation
+
Location and sublocation of the primary tumour according to ICD-O-3.
|
valuelist
+
the table shows a selection of 12 values
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | morf | Morphology
+
Histological type of the tumour (first four digits of the ICD-O morphology code) according to ICD-O-3.2.
|
valuelist
+
the table shows a selection of 12 values
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | morf_cat | Morphology (categories)
+
Subdivision into subgroups within the carcinoma tumour type. Intended, among other purposes, to enable a more precise selection of adenocarcinoma (AC) or hepatocellular carcinoma (HCC). Some rare variants (according to RareCareNet) are classified as separate categories. Neuroendocrine tumours, blastomas, sarcomas and lymphomas are excluded.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | gedrag | Behaviour
+
Tumour behaviour (fifth digit of the ICD-O morphology code).
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | diffgrad | (Differentiation) grade
+
Tumour differentiation grade (sixth digit of the ICD-O morphology code)
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | ct | cT (TNM)
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2021 for cervical carcinomas
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | cn | cN (TNM)
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2021 for cervical carcinomas
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | cm | cM (TNM)
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2021 for cervical carcinomas
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | pt | pT (TNM)
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2021 for cervical carcinomas
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | pn | pN (TNM)
+
The TNM classification uses the edition applicable at the time of incidence.
Meaning of the last character in pN:
S: Result based only on sentinel node examination (sn)
I: Isolated tumour cells (ITC)
M: Micrometastases (mi)
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | pm | pM (TNM)
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2021 for cervical carcinomas
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | cstadium | Clinical TNM stage
+
cstadium: The clinical stage is based on cTNM, which is derived from information available before (neo-adjuvant) treatment, including findings during surgery (if not treated neo-adjuvantly) that influence the treatment plan.
Meaning of "X" (unknown): Stage cannot be calculated, e.g., TX/NX/M0. Meaning of "M" (missing): Indicates TNM not recorded, possibly due to incomplete registration or use of EoD staging instead of TNM. Meaning of "NVT" (not applicable): TNM staging does not apply to this tumour type for the given incidence period.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | pstadium | Pathological TNM stage
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
pstadium: The pathological (post-surgical) stage is based on pT, pN and pM. Also in case of pre-surgical therapy, pT and pN are used (ypT and ypN). When no tumour is detectable after pre-surgical therapy, this is shown as pstadium=0.
pM: Indicates whether there is pathological confirmation of distant metastases. There may be distant metastases that are not pathologically confirmed, which are therefore not included in the calculation for this variable.
Meaning of "X" (unknown): Stage cannot be calculated, e.g., TX/NX/M0.
Meaning of "M" (missing): Indicates TNM not recorded, possibly due to incomplete registration or use of EoD staging instead of TNM.
Meaning of "NVT" (not applicable): TNM staging does not apply to this tumour type for the given incidence period.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | stadium | TNM stage
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
Stadium: Based on pTNM supplemented by cTNM to best reflect the actual stage at diagnosis. Priority is given to pTNM values. If surgery did not occur, pTNM is unknown, or pre-surgical therapy was given (pTNM becomes ypTNM), cTNM values are used.
Meaning of "X" (unknown): Stage cannot be calculated, e.g., TX/NX/M0.
Meaning of "M" (missing): Indicates TNM not recorded, possibly due to incomplete registration or use of EoD staging instead of TNM.
Meaning of "NVT" (not applicable): TNM staging does not apply to this tumour type for the given incidence period.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | ceod | Clinical tumour extension (EoD)
+
The 'Extent of Disease' (EoD) staging is used for solid tumours where no standard staging system such as TNM exists. EoD staging was also used for morphology M8000 (no pathological confirmation) until incidence date 01-01-2012.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | peod | Pathological tumour extension (EoD)
+
The 'Extent of Disease' (EoD) staging is used for solid tumours where no standard staging system such as TNM exists. EoD staging was also used for morphology M8000 (no pathological confirmation) until incidence date 01-01-2012.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | ond_lymf | Number of regional lymph nodes examined
+
All lymph nodes examined as part of initial diagnostics and treatment combined.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | pos_lymf | Number of positive regional lymph nodes | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | diag_basis | Basis for diagnosis
+
Non-microscopic confirmation:
0 = death certificate only
1 = clinical examination only (medical history and physical)
2 = clinical diagnostic tests, exploratory surgery or autopsy (without microscopic confirmation)
4 = specific biochemical and/or immunological laboratory tests.
Microscopic confirmation:
5 = haematological (bone marrow cytology, e.g., bone marrow aspiration, blood smear) or cytological confirmation of primary tumour or metastases, or definite microscopic confirmation but unclear whether cytology or histology
6 = histological confirmation of metastases only, including at autopsy
7 = histological confirmation of primary tumour, or unclear whether histology refers to primary tumour or
metastasis, including autopsy with histology.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | afp | Alpha-fetoprotein (AFP) (µg/L)
+
Refers to the most recent value prior to treatment initiation or the decision whether or not to treat. Values above 9000 are recorded as 9000. Available for hepatocellular carcinoma from 2014 and for intrahepatic cholangiocarcinoma from 2018.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | albumine | Albumin (g/L)
+
Refers to the most recent value prior to treatment initiation or the decision whether or not to treat.
Available for hepatocellular carcinoma since 2014, for pancreatic carcinoma since 2015, for periampullary carcinoma since 2016, and for intrahepatic cholangiocarcinoma since 2018.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | arterieel_vaatbetr | Arterial vascular involvement based on imaging
+
Available for pancreatic and peri-ampullary carcinoma from 2016 onwards.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | bclc | BCLC classification
+
Available for hepatocellular carcinoma from 2014 onwards.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | beeld_m0 | M0 on imaging
+
Available from 2015 for all HPB tumours.
The imaging status is not explicitly recorded as such in the NKR, but is derived based on the assumption that no distant metastasis/metastases were observed on imaging prior to the start of tumour treatment (beeld_m0 value 1 - Yes) if:
-the tumour was diagnosed as an incidental finding during surgery performed for another indication
-no metastasis/metastases are known with an incidence date prior to the first tumor-directed treatment, surgical exploration without resection, or diagnostic laparoscopy
-the above does not apply and cM = 0 or unknown (in the case of tumours for which cEoD is registered: cEoD not value 6).
-In the case of tumour treatment and metastases with an unknown incidence date, beeld_m0 is assigned value 9 - Unknown.
Distant metastases have been systematically registered since incidence year 2008; however, incidence dates of distant metastases have only been recorded since incidence year 2015.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | bilirubine | Total bilirubin (µmol/L)
+
Refers to the highest value prior to treatment initiation or the decision whether or not to treat. In patients with a biliary stent or PTC drain, the total bilirubin level recorded is the value before biliary drainage. Available for hepatocellular carcinoma from 2014; for pancreatic carcinoma, cholangiocarcinoma and papillary carcinoma from 2015; and for gallbladder and duodenal carcinoma from 2016.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | bismuth_corlette | Bismuth-Corlette classification
+
Available for perihilar cholangiocarcinoma from 2020 onwards.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | ca199 | Carbohydrate antigen 19-9 (CA19-9) (kU/L = U/ml)
+
Refers to the most recent value prior to treatment initiation or the decision whether or not to treat. Values above 9000 are recorded as 9000.
Available for pancreatic carcinoma from 2015, for periampullary carcinoma from 2016, and for all cholangiocarcinomas and gallbladder carcinoma from 2020.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | cea | Carcinoembryonic antigen (CEA) (µg/L)
+
Refers to the most recent value prior to treatment initiation or the decision whether or not to treat. Available from 2020 for all HPB cancers.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | crp | C-reactive protein (CRP) (mg/L)
+
Refers to the most recent value prior to treatment initiation or the decision whether or not to treat. Available for pancreatic carcinoma from 2015 and for periampullary carcinoma from 2016.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | hb | Haemoglobin (mmol/L)
+
Refers to the most recent value prior to treatment initiation or the decision whether or not to treat. Available for pancreatic carcinoma between 2015-2020, and for periampullary carcinoma between 2016-2020.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | inr | International Normalised Ratio (INR)
+
Refers to the most recent value prior to treatment initiation or the decision whether or not to treat. Available for hepatocellular carcinoma from 2014 and for intrahepatic cholangiocarcinoma from 2018.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | klin_tum_afm | Maximum clinical diameter of the primary tumour (mm)
+
Largest diameter based on the (most recent) radiology report prior to the initiation of tumour-directed therapy or the decision not to treat.
Available for hepatocellular carcinoma from 2014, for pancreatic carcinoma from 2015, for periampullary carcinoma from 2016, for intrahepatic cholangiocarcinoma from 2018, and from 2020 onwards for all primary HPB tumours.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | kreatinine | Creatinine (µmol/L)
+
Refers to the most recent value prior to treatment initiation or the decision whether or not to treat.
Available for hepatocellular carcinoma since 2014, for pancreatic carcinoma between 2015-2020, for periampullary carcinoma between 2016-2020, and for intrahepatic cholangiocarcinoma since 2018.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | ldh | Lactate dehydrogenase (U/L)
+
Refers to the highest value prior to treatment initiation or the decision whether or not to treat.
Available from 2015 onwards for pancreatic carcinoma, from 2016 onwards for peri-ampullary carcinoma, and from 2018 onwards for Intrahepatic cholangiocarcinom.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | lymfocyten | Lymphocyte count (x10^9/L)
+
Refers to the most recent value prior to treatment initiation or the decision whether or not to treat. Available for pancreatic carcinoma from 2015.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | meta_incdat | Incidence date of metastasis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | meta_int | Interval between incidence date and date of metastasis (days)
+
The incidence date is defined as the date of the first histological or
cytological confirmation of the primary tumour.
The metastasis date refers to the first histological or cytological confirmation of the
metastasis. If histological confirmation does not occur within three
months, the clinical diagnosis date is used. Consequently, the
metastasis date may precede the primary tumour incidence date by up
to three months.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | meta_topo_sublok | Topography including sublocation of metastasis
+
Metastasis location according to ICD-O-3. Metastatic sites have been recorded nationwide since 2008. For distant metastases at more than three sites, C768 was coded up to 2014 to indicate more than three locations. In 2017/2018 C768 may indicate more than four locations.
Explanation for records where both cM and pM show no metastases despite metastatic sites being recorded at diagnosis: cTNM is based on information available before (neo-adjuvant) treatment, including findings during surgery (if not treated neo-adjuvantly) that influence the treatment plan. pM indicates whether pathological
confirmation exists for distant metastases. If metastases are detected during or after neo-adjuvant treatment, TNM is not updated, but metastasis locations are recorded.
If the dataset includes metastasis locations after progression: only new or enlarged metastases are recorded, not all existing ones. C809 is coded for clinical progression when the site is unknown.
|
valuelist
+
the table shows a selection of 12 values
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | meta_topo | Topography excluding sublocation of metastasis
+
Metastasis location according to ICD-O-3. Metastatic sites have been recorded nationwide since 2008. For distant metastases at more than three sites, C768 was coded up to 2014 to indicate more than three locations. In 2017/2018 C768 may indicate more than four locations.
Explanation for records where both cM and pM show no metastases despite metastatic sites being recorded at diagnosis: cTNM is based on information available before (neo-adjuvant) treatment, including findings during surgery (if not treated neo-adjuvantly) that influence the treatment plan. pM indicates whether pathological
confirmation exists for distant metastases. If metastases are detected during or after neo-adjuvant treatment, TNM is not updated, but metastasis locations are recorded.
If the dataset includes metastasis locations after progression: only new or enlarged metastases are recorded, not all existing ones. C809 is coded for clinical progression when the site is unknown.
|
valuelist
+
the table shows a selection of 12 values
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | meta_lok_aantal | Number of topographic locations with metastases present
+
If metastases fall within the main groups (peritoneum, lung, bone, liver, brain, lymph node, or adrenal gland), they are counted as one location. All other metastases are counted by unique two-digit ICD-O locations. Between 2008 and 2014, not all locations were recorded for patients with more than three metastatic sites; for these patients, the number of metastatic sites is recorded as 77.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | meta_bijnier | Adrenal metastasis/metastases present
+
Available since 2008. Metastases in the adrenal gland (C74). Between 2008 and 2014, not all sites were recorded for patients with more than three metastatic sites; similarly for more than four sites in 2017/2018.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | meta_bot | Bone metastasis/metastases present
+
Available since 2008. Metastases in bone or bone marrow (C40, C41, C421). Between 2008 and 2014, not all sites were recorded for patients with more than three metastatic sites; similarly for more than four sites in 2017/2018.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | meta_hersenen | Brain metastasis/metastases present
+
Available since 2008. Brain metastases (C71). Between 2008 and 2014, not all sites were recorded for patients with more than three metastatic sites; similarly for more than four sites in 2017/2018.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | meta_lever | Liver metastasis/metastases present
+
Available since 2008. Liver metastases (C22). Between 2008 and 2014, not all sites were recorded for patients with more than three metastatic sites; similarly for more than four sites in 2017/2018.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | meta_long | Lung metastasis/metastases present
+
Available since 2008. Lung metastases excluding pleural metastases (C34). Between 2008 and 2014, not all sites were recorded for patients with more than three metastatic sites; similarly for more than four sites in 2017/2018.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | meta_lymf | Non-regional lymph node metastasis/metastases present
+
Available since 2008. Metastases in non-regional lymph nodes (C77). Between 2008 and 2014, not all sites were recorded for patients with more than three metastatic sites; similarly for more than four sites in 2017/2018.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | meta_overig | Other metastasis/metastases present
+
Available since 2008. Between 2008 and 2014, not all sites were recorded for patients with more than three metastatic sites; similarly for more than four sites in 2017/2018.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | meta_perit | Peritoneal metastasis/metastases present
+
Available since 2008. All metastases in the (retro)peritoneum (C48). Between 2008 and 2014, not all sites were recorded for patients with more than three metastatic sites; similarly for more than four sites in 2017/2018.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | multifoc | Tumour multifocality
+
Available for hepatocellular carcinoma and intrahepatic bile duct cancers, with limited completeness. In recent years, the number of liver nodules has been routinely recorded.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | neutrofielen | Neutrophil count (x10^9/L)
+
Refers to the most recent value prior to treatment initiation or the decision whether or not to treat. Available for pancreatic carcinoma from 2015.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | noduli | Number of nodules of the primary tumour in the liver
+
Number of tumour lesions diagnosed in the liver based on imaging performed prior to the start of tumour-directed therapy. Available for hepatocellular carcinoma from 2014 onwards and for intrahepatic cholangiocarcinoma from 2018 onwards.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | pa_tum_afm | Maximum pathological diameter of the primary tumour (mm)
+
Available for pancreatic carcinoma from 2015 onwards and for peri-ampullary carcinoma from 2016 onwards.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | resectabiliteit | Resectability of the tumour based on vascular involvement
+
Available from 2016 for pancreatic and peri-ampullary carcinoma. Classification is based on venous and arterial vascular involvement according to the DPCG definition (PREOPANC 2012, http://www.dpcg.nl/richtlijnen/).
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | trombocyten | Platelet count (x10^9/L)
+
Refers to the most recent value prior to treatment initiation or the decision whether or not to treat. Available for pancreatic carcinoma from 2015.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | veneus_vaatbetr | Venous vascular involvement based on imaging
+
Available for pancreatic and peri-ampullary carcinoma from 2016 onwards.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | ycm | ycM (TNM)
+
ycTNM is recorded when neoadjuvant therapy is not followed by surgery. Available for pancreatic carcinoma from 2015 onwards.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | ycn | ycN (TNM)
+
ycTNM is recorded when neoadjuvant therapy is not followed by surgery. Available for pancreatic carcinoma from 2015 onwards.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | yct | ycT (TNM)
+
ycTNM is recorded when neoadjuvant therapy is not followed by surgery. Available for pancreatic carcinoma from 2015 onwards.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | contact_zkh1 | Hospital of first contact regarding malignancy
+
The first hospital visited by the patient for symptoms related to the malignancy, and where, based on that visit, a (suspected) malignancy is determined.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | contact_zkh1_consult_dat | Date of first consultation at the hospital of initial contact related to the malignancy
+
Available since 2015. The first hospital visited by the patient for symptoms related to the malignancy.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | contact_zkh1_consult_int | Interval between incidence date and first hospital consultation
+
Available since 2015. The first hospital visited by the patient for symptoms related to the malignancy.
The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | curatief_behplan | Treatment plan with curative intent
+
Treatment plan prior to the start of tumour-directed therapy
Available for pancreatic carcinoma from 2015, for periampullary carcinoma from 2016, and from 2020 for all primary HPB tumours.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | diag_lap_dat[1-2] | Date of diagnostic laparoscopy[1-2]
+
Complete from 2012 onwards. Partially recorded for incidence years 2009-2011 (only if a diagnostic laparoscopy was recorded); however, diagnostic laparoscopies were not consistently recorded in those years.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | diag_lap_int[1-2] | Interval between incidence date and date of diagnostic laparoscopy (days)[1-2]
+
Complete from 2012 onward. Partially complete (if a diagnostic laparoscopy is known) for incidence years 2009-2011. However, for these years diagnostic laparoscopies will not always have been recorded.
The date of incidence is defined as the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | diag_lap | Diagnostic laparoscopy performed
+
Complete from 2012 onwards. Partially recorded for incidence years 2009-2011 (only if a diagnostic laparoscopy was recorded); however, diagnostic laparoscopies were not consistently recorded in those years. As a result, only value 1/yes occurs for these y
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | diag_reden | Reason for diagnostic assessment
+
Available from 2017 for HCC.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | diag_lap_uitslag[1-2] | Result of diagnostic laparoscopy[1-2]
+
Complete from 2012 onwards. Partially recorded for incidence years 2009-2011 (only if a diagnostic laparoscopy was recorded); however, diagnostic laparoscopies were not consistently recorded in those years.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | diag_lap_zkh[1-2] | Hospital where diagnostic laparoscopy was performed[1-2]
+
Complete from 2012 onwards. Partially recorded for incidence years 2009-2011 (only if a diagnostic laparoscopy was recorded); however, diagnostic laparoscopies were not consistently recorded in those years.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | expert_bel_ther_zkh | Hospital of main treatment is a specialised centre
+
Available from 2011
Hospital of primary treatment:
Patients who are treated for a tumour at more than one hospital are assigned to the hospital where the most intensive treatment was performed, based on the following prioritization:
1. Hospital where the most extensive surgical procedure was performed
2. Hospital where the patient received systemic therapy
3. Hospital where another type of treatment was provided (excluding radiotherapy)
4. Hospital where the diagnosis was mad
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | expert_contact_zkh1 | Hospital of first contact related to the malignancy is a specialised centre
+
Available since 2011.
Hospital of first contact: The first hospital visited by the patient for symptoms related to the malignancy, and where, based on that visit, a (suspected) malignancy is determined.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | mdo | Discussed in multidisciplinary team meeting
+
Available from 2014, with involvement of a specialised centre from 2017 onwards.
Between 2014 and 2016, the determination of specialised centre involvement for this variable was based on the center where the multidisciplinary team meeting (MDT) took place, rather than on whether a specialised centre was actually involved.
In principle, the last MDT in which a decision about therapy was made is recorded. If no MDT was conducted prior to the start of therapy, the first MDT carried out after the start of therapy is recorded.
Please note: the MDT is not routinely registered in all hospitals and may therefore more often be recorded as unknown for certain hospitals.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | mdo_voor_ther | Discussed in MDT prior to initiation of tumour-directed therapy
+
Available from 2014, with involvement of a specialised centre from 2017 onwards. For the start of therapy, this variable includes not only tumour-directed therapy that has been performed but also exploratory surgery (an intended curative procedure that is aborted due to inoperability or the patient's condition). Surgery for another indication with an incidental finding at pathology (PA) is not included.
Between 2014 and 2016, the determination of specialised centre involvement for this variable was based on the center where the multidisciplinary team meeting (MDT) took place, rather than on whether a specialised centre was actually involved.
In principle, the last MDT in which a decision about therapy was made is recorded. If no MDT was conducted prior to the start of therapy, the first MDT carried out after the start of therapy is recorded.
Please note: the MDT is not routinely registered in all hospitals and may therefore more often be recorded as unknown for certain hospitals.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | zkh_patnum | Patient number in hospital | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Risk factors | asa | ASA classification
+
Available from 2015 onwards for pancreatic carcinoma, from 2016 onwards for peri-ampullary carcinoma, and from 2020 onwards for hepatobiliary carcinoma.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Risk factors | cci | Charlson Comorbidity Index (weighted)
+
The yes/no variables for categories are summarised in cci_cat (0, 1, 2 or more) and cci (weighted score per
Charlson 1987), with some categories counted only once if both occur:
• Cerebrovascular disease and Hemiplegia
• Diabetes and Diabetes with end organ damage
• Mild liver disease and Moderate/severe liver disease
• Any tumour and Metastatic solid tumour
Alternative summary scoring methods may also be used.
Incomplete scores:
From 2019, registration aligns with the Charlson Comorbidity Index. Earlier records may lack complete category data, leading to some misclassification, noted in the relevant variable.
Note: From 1995 to 2014, comorbidities were recorded only in the southern Netherlands. From 2015, coverage is sometimes national but not for all tumour types or years. Missing variables indicate no comorbidities recorded for that tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Risk factors | cci_aids | AIDS (including HIV) according to the Charlson Comorbidity Index |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Risk factors | cci_cat | Number of categories according to the Charlson Comorbidity Index
+
The yes/no variables for categories are summarised in cci_cat (0, 1, 2 or more) and cci (weighted score per
Charlson 1987), with some categories counted only once if both occur:
• Cerebrovascular disease and Hemiplegia
• Diabetes and Diabetes with end organ damage
• Mild liver disease and Moderate/severe liver disease
• Any tumour and Metastatic solid tumour
Alternative summary scoring methods may also be used.
Incomplete scores:
From 2019, registration aligns with the Charlson Comorbidity Index. Earlier records may lack complete
category data, leading to some misclassification, noted in the relevant variable.
Note: From 1995 to 2014, comorbidities were recorded only in the southern Netherlands. From 2015, coverage is sometimes national but not for all tumour types or years. Missing variables indicate no comorbidities recorded for that tumour.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Risk factors | cci_chf | Congestive heart failure according to the Charlson Comorbidity Index |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Risk factors | cci_collagenosis | Collagenosis according to the Charlson Comorbidity Index |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Risk factors | cci_copd | Chronic obstructive pulmonary disease according to the Charlson Comorbidity Index |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Risk factors | cci_cvd | Cerebrovascular disease according to the Charlson Comorbidity Index
+
Since 2019, registration has been aligned with the Charlson Comorbidity Index. For earlier years, not all categories can be accurately determined. Up to around 2012: Cci_cvd did not include TIA but did include significant carotid stenosis (treated with carotid endarterectomy or carotid desobstruction). As a result, patients may have been incorrectly included or excluded from the cerebrovascular disease category.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Risk factors | cci_dementia | Dementia according to the Charlson Comorbidity Index |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Risk factors | cci_dm | Diabetes mellitus according to the Charlson Comorbidity Index
+
From 2019 onwards, registration aligns with the Charlson Comorbidity Index For registrations from earlier years, not all categories can therefore be accurately determined. Up to around 2018: Diabetes managed by diet alone was included in the registration.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Risk factors | cci_eod_dm | Diabetes with end-organ damage according to the Charlson Comorbidity Index |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Risk factors | cci_mild_liver | Mild liver disease according to the Charlson Comorbidity Index
+
Since 2019, registration has been aligned with the Charlson Comorbidity Index. For earlier years, not all categories can be accurately determined. Up to around 2018: No distinction was made between mild and moderate or severe liver disease. These patients were all included under cci_liver1 instead of cci_liver2. This does not affect cci_cat but does affect category classification and CCI.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Risk factors | cci_severe_liver | Severe or moderate liver disease according to the Charlson Comorbidity Index
+
Since 2019, registration has been aligned with the Charlson Comorbidity Index. For earlier years, not all categories can be accurately determined. Up to around 2018: No distinction was made between mild and moderate or severe liver disease. These patients were all included under cci_liver1 instead of cci_liver2. This does not affect cci_cat but does affect classification into categories and the CCI index.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Risk factors | cci_malignancy | Other malignancy according to the Charlson Comorbidity Index
+
Previous or concurrent invasive/malignant cancers, excluding basal cell and squamous cell carcinomas of the skin, where the initial diagnosis occurred between five years before and 30 days after the diagnosis of this tumou
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Risk factors | cci_metastatic | Other metastatic solid tumour according to the Charlson Comorbidity Index
+
Previous or synchronous metastatic cancer diagnosed up to 30 days after the diagnosis of this tumour. The NCR does not have complete registration of metachronous metastases. For many tumour types, these have only been recorded systematically or project-based in recent years, so this variable may sometimes incorrectly show as 0.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Risk factors | cci_mi | Myocardial infarction according to the Charlson Comorbidity Index
+
Since 2019, registration has been aligned with the Charlson Comorbidity Index. For earlier years, not all categories can be accurately determined. Up to around 2012: Cci_mi also included angina pectoris, meaning patients may have been incorrectly included in this variable.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Risk factors | cci_plegia | Hemiplegia or paraplegia according to the Charlson Comorbidity Index |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Risk factors | cci_pvd | Peripheral vascular disease according to the Charlson Comorbidity Index |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Risk factors | cci_renal | Moderate or severe renal disease according to the Charlson Comorbidity Index
+
Since 2019, registration has been aligned with the Charlson Comorbidity Index. For earlier years, not all categories can be accurately determined. Up to around 2018: Cci_renal also included mild kidney disease, meaning patients may have been incorrectly included in the category moderate or severe renal disease.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Risk factors | cci_ulcer | Ulcer disease according to the Charlson Comorbidity Index |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Risk factors | child_pugh | Child-Pugh classification
+
Available for hepatocellular carcinoma from 2014 onwards and for intrahepatic cholangiocarcinoma from 2020 onwards.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Risk factors | diag_gewicht | Weight at diagnosis (kg)
+
Available nationwide in 2015, and subsequently limited to one region.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Risk factors | gebr_gewicht | Usual weight (kg)
+
Available nationwide in 2015, and subsequently limited to one region.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Risk factors | lengte | Patient height (cm)
+
Available nationwide in 2015, and subsequently limited to one region.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Risk factors | levercirrose | Liver cirrhosis present
+
Available from 2014 for HCC and from 2020 onwards for intrahepatic bile duct cancers. For HCC, this is determined based on a combination of classifications.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Risk factors | perf_stat | WHO performance status before start of therapy
+
WHO performance status before starting therapy. If the Karnofsky score is noted in the medical record, it is converted to WHO score as described in Ma et al. 2010 - Interconversion of three measures of performance status: An empirical analysis. Performance status data has been recorded for pancreatic carcinoma since 2015, hepatocellular carcinoma since 2014, periampullary carcinoma since 2016, and other biliary carcinomas since 2018.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Risk factors | risicofactor | Risk factors for hepatocellular carcinoma
+
Available for hepatocellular carcinoma from 2014 onwards. Where multiple risk factors are present, the highest score (1-6) is recorded.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | bypass | Bypass procedure performed by surgeon
+
Available from 2012. Bypass procedure to improve bile drainage and/or food passage (no resection).
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | bypass_dat[1-2] | Date of bypass procedure[1-2]
+
Available since 2012.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | bypass_int[1-2] | Interval between incidence date and date of bypass procedure (days)[1-2]
+
Available since 2012.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | bypass_chir_tech[1-2] | Surgical technique of the bypass procedure[1-2]
+
Available since 2012.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | bypass_type[1-2] | Type of bypass procedure performed by the surgeon[1-2]
+
Available from 2012. The first two bypass-related procedures are recorded.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | bypass_zkh[1-2] | Hospital where bypass procedure was performed[1-2]
+
Available since 2012.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chemo | Systemic chemotherapy classified as pre- or post-surgical
+
Determination of pre- and post-surgical therapy is based on the chronological order of procedures in the NCR. The first surgical resection is used as the reference point. Local surgical procedures (e.g. polypectomy, excision biopsy, TUR, photodynamic therapy, electrocautery, cryosurgery, radiofrequency ablation) are excluded from this determination.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chemort | Chemoradiation classified as pre- or post-surgical
+
Both chemotherapy and radiotherapy were part of the treatment, and based on dates/types, this likely represents chemoradiation. Up to 2011, this variable may be incomplete because start and end dates for chemotherapy and radiotherapy were not always recorded. The chemotherapy and radiotherapy components are also included in the variables for systemic chemotherapy and radiotherapy.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chir | Surgery performed |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chir_dat[1-2] | Date of surgery[1-2]
+
Available since 2005.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chir_int[1-2] | Interval between incidence date and date of surgery (days)[1-2]
+
Available since 2005. The incidence date is the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chir_opnameduur[1-2] | Length of hospital stay after surgery (days)[1-2]
+
Available from 2011. Recording is incomplete from 2020 onwards.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chir_rad[1-2] | Radicality of surgery[1-2]
+
Available from 2015. This item is used for invasive tumours to indicate whether residual tumour is present after a resection aimed at the primary tumour (T). This item does not concern regional lymph nodes or distant metastases.
In determining radicality, only the invasive primary tumour is considered. Any in situ component or lymph nodes in the resection specimen are not included in the assessment of the radicality of the primary tumour.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chir_tech[1-2] | Surgical technique[1-2]
+
Surgical technique data are available from 2010 for all HPB cancers. Robot-assisted surgery is available from 2015 for pancreatic resections and from 2018 for other HPB resections.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chir_toeval | Tumour was an incidental finding during surgery for another indication |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chir_type[1-2] | Type of surgery[1-2]
+
From 2005 onwards, the type of surgery has been recorded in greater detail. Prior to 2005 it was usually classified as 99 (other/unknown).
The type of surgery can be more broadly categorised based on the first digit of the outcome value:
1 = local resection, 2 = pancreatic resection, 3 = liver resection, 4 = biliary/periampullary resection, and 9 = other/unknown.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chir_vaten[1-2] | Resection of major vessels during surgery[1-2]
+
Available from 2015 for pancreatic and peri-ampullary carcinoma.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chir_zkh[1-2] | Hospital where surgery was performed[1-2] |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | curatief_chir | Surgery performed with curative intent
+
Available from 2009 for all HPB tumours. Based on the assumption that all resections of the primary tumour and surgical explorations without resection were initiated with curative intent. Diagnostic laparoscopy is not included. For hepatocellular carcinoma (HCC), ablation procedures are also included.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | curatief_chir_dat | Date of first surgery with curative intent | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | curatief_chir_int | Interval incidence date and date of first surgery with curative intent (days)
+
Available since 2009. The incidence date is the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | destr | Tumour destruction performed
+
Destruction of the primary tumour using heat, radiation, cold, or similar techniques.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | destr_aantal | Total number of tumour destruction procedures performed
+
Total number of times tumour destruction was performed as part of the initial treatment following diagnosis.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | destr_dat[1-2] | Date of tumour destruction[1-2]
+
Available since 2005.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | destr_int[1-2] | Interval incidence date and date of tumour destruction (days)[1-2]
+
Available since 2005. The incidence date is the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | destr_type[1-2] | Type of tumour destruction[1-2]
+
Destruction of the primary tumour using heat, radiation, cold, or similar techniques.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | destr_zkh[1-2] | Hospital where tumour destruction was performed[1-2] |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | embolisatie | Hepatic embolisation performed
+
Embolisation used as preparation for local treatment of liver tumours, but not in combination with radiotherapy or chemotherapy.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | expl_chir | Exploratory surgery performed
+
Available from 2009. Exploratory surgery is a procedure initially intended to be curative but discontinued due to inoperability or the patient's clinical condition.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | expl_chir_dat[1-2] | Date of exploratory surgery[1-2]
+
Available from 2009. Exploratory surgery is a procedure initially intended to be curative but discontinued due to inoperability or the patient's clinical condition.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | expl_chir_int[1-2] | Interval between incidence date and date of exploratory surgery (days)[1-2]
+
Available from 2009. Exploratory surgery is a procedure initially intended to be curative but discontinued due to inoperability or the patient's clinical condition.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | expl_chir_uitslag[1-2] | Result of exploratory surgery[1-2]
+
Available from 2009. Exploratory surgery is a procedure initially intended to be curative but discontinued due to inoperability or the patient's clinical condition.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | expl_chir_zkh[1-2] | Hospital where exploratory surgery was performed[1-2]
+
Available from 2009. Exploratory surgery is a procedure initially intended to be curative but discontinued due to inoperability or the patient's clinical condition.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | galafvloed | Stent or drain placed to improve biliary drainage
+
Available since 2015.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | galafvloed_dat[1-2] | Date of procedure to improve bile drainage[1-2]
+
Available since 2015.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | galafvloed_int[1-2] | Interval incidence date and date of a procedure to improve biliary drainage (days)[1-2]
+
Available since 2015.
The incidence date is the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | galafvloed_stent_tech[1-2] | Stent technique used to improve biliary drainage[1-2]
+
Available from 2018 for stent placement.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | galafvloed_type[1-2] | Type of procedure to improve biliary drainage[1-2]
+
Available from 2015. The first two procedures related to bile drainage prior to the start of tumour treatment are recorded.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | galafvloed_zkh[1-2] | Hospital where a procedure to improve biliary drainage was performed[1-2] |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | geen_ther_reden | Reason for not performing tumour-directed therapy
+
Available from 2014 if no tumour-directed therapy has been performed (variable tumgericht_ther = 0).
From 2015 onwards, a reason is also recorded in cases where a tumour-directed subsequent therapy was not performed despite the patient having an indication according to the guideline. The type of this non-performed tumour-directed subsequent therapy is recorded in the variable geen_ther_type, with the corresponding sequence number. These items have been incompletely recorded.
If multiple reasons are recorded, one reason is selected based on the following hierarchy: value 11 > 12 > 13 > 14 > 8 > 9.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | geen_ther_type | Reason for no tumour-directed follow-up therapy
+
Available from 2015 when tumour-directed follow-up therapy was not administered despite an indication according to the guideline. The reason why no tumour-directed follow-up therapy was given is recorded in the variable geen_ther_reden. These items are incompletely recorded.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | lkd | Lymph node dissection performed during gallbladder resection
+
Available from 2020 for gallbladder cancer.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | lok_chemo_aantal | Total number of local chemotherapy treatments administered
+
Number of times local chemotherapy was administered as part of the initial treatment following diagnosis.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | lok_chemo | Local chemotherapy performed
+
Local chemotherapy administered to the primary tumour.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | lok_chemo_dat[1-2] | Date of local chemotherapy[1-2]
+
Available since 2007.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | lok_chemo_int[1-2] | Interval incidence date and date of local chemotherapy (days)[1-2]
+
Available since 2007. The incidence date is the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | lok_chemo_type[1-2] | Type of local chemotherapy[1-2]
+
Local chemotherapy administered to the primary tumour.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | lok_chemo_zkh[1-2] | Hospital where local chemotherapy was administered[1-2] |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | meta_chir | Surgery targeting metastases performed |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | meta_rt | Radiotherapy targeting metastases performed |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | prechir_intent | Preoperative systemic therapy with intent to resection
+
Available from incidence year 2009 if resection or surgical exploration was preceded by chemo(radio)therapy. From 2016 onwards, pre-surgical therapy without subsequent surgery (resection or exploration) is available (value 3), though completeness may be limited.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | reresectie | Re-resection performed
+
Available from 2011. This concerns a second resection of the primary tumour and/or regional lymph nodes. Some incompleteness may exist in the early years.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | reresectie_rest | Residual tumour in re-resection
+
Available from 2020 for gallbladder cancer.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | respons_dat | Date of response assessment
+
Available from 2015 onwards for pancreatic tumours, from 2017 onwards for HCC, and from 2020 onwards for all primary HPB tumours. Recorded for patients receiving systemic therapy, excluding post-surgical therapy. Where multiple response assessments were available, the 'best' or 'most favourable' response was recorded.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | respons_int | Interval incidence date and date of response assessment (days)
+
Available from 2015 onwards for pancreatic tumours, from 2017 onwards for HCC, and from 2020 onwards for all primary HPB tumours. Recorded for patients receiving systemic therapy, excluding post-surgical therapy. Where multiple response assessments were available, the 'best' or 'most favourable' response was recorded. The incidence date is defined as the date of first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | respons_uitslag | Result of response assessment
+
Available from 2015 onwards for pancreatic tumours, from 2017 onwards for HCC, and from 2020 onwards for all primary HPB tumours. Recorded for patients receiving systemic therapy, excluding post-surgical therapy. Where multiple response assessments were available, the 'best' or 'most favourable' response was recorded.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | rt | Radiotherapy classified as pre- or post-surgical
+
This variable refers to radiotherapy targeting the primary tumour.
Determination of pre- and post-surgical therapy is based on the chronological order of procedures in the NCR. The first surgical resection is used as the reference point. Local procedures (e.g. tumour destruction, excision biopsy, photodynamic therapy, electrocautery, cryosurgery, radiofrequency ablation) are excluded from this determination.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | rt_aantal | Total number of radiotherapy treatments administered
+
Number of times radiotherapy targeting the primary tumour was initiated as part of the initial treatment following diagnosis.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | rt_start_int[1-2] | Interval between incidence date and start date of radiotherapy (days)[1-2]
+
Available since 2007. The incidence date is the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | rt_stop_int[1-2] | Interval between incidence date and end date of radiotherapy (days)[1-2]
+
Available since 2011. The incidence date is the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | rt_startdat[1-2] | Start date of radiotherapy[1-2]
+
Available since 2007.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | rt_stopdat[1-2] | End date of radiotherapy[1-2]
+
Available since 2011.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | rt_type[1-2] | Type of radiotherapy[1-2]
+
Refers to radiotherapy targeting the primary tumour.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | rt_zkh[1-2] | Hospital where radiotherapy was performed[1-2] |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | syst_code | Code for systemic therapy
+
Systemic therapies in the NCR are coded using the Anatomical Therapeutic Chemical (ATC) classification system. Recording of systemic therapy is not always specific; before 2015, non-specific codes were used more frequently.
|
valuelist
+
the table shows a selection of 12 values
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | syst_compl | Complicated course after systemic therapy
+
Available from 2021 for pancreatic carcinoma. Registration is incomplete.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | syst_dosisreductie | Dose reduction in systemic therapy
+
Available since 2015.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | syst_start_int | Interval between incidence date and start date of systemic therapy (days)
+
The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | syst_stop_int | Interval between incidence date and end date of systemic therapy (days)
+
The end date of chemotherapy is the day the final cycle is completed. If this date is unknown, the start date of the last cycle may be recorded as the end date. The incidence date is the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | syst_kuren | Number of systemic therapy cycles |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | syst_startdat | Start date of systemic therapy | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | syst_stopdat | End date of systemic therapy
+
The end date of chemotherapy is the day the final cycle is completed. If this date is unknown, the start date of the last cycle may be recorded as the end date.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | syst_zkh | Hospital where systemic therapy was administered |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | target | Systemic targeted therapy classified as pre- or post-surgical
+
This variable refers to systemic targeted therapy, including immunotherapy.
Determination of pre- and post-surgical therapy is based on the chronological order of procedures in the NCR. The first surgical resection is used as the reference point. Local procedures (e.g. tumour destruction, excision biopsy, photodynamic therapy, electrocautery, cryosurgery, radiofrequency ablation) are excluded from this determination.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | transplant | Liver transplant performed
+
Refers to liver transplantation performed due to malignancy. From 2017 onwards, liver transplantation for underlying liver disease and partial liver transplantation are also recorded. Due to waiting list dynamics, the transplant procedure itself may not y
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | transplant_wachtlijst | Patient is on the waiting list for liver transplantat
+
Available from 2022 for liver and bile duct cancers. Indicates whether the patient is on, or is being placed on, the liver transplant waiting list at the time of registration.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | tumgericht_ther_start_int1 | Interval incidence date and start date of first tumour-directed therapy (days)
+
Available from 2011. In the period 2005-2010, mainly available if a resection was performed.
The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | tumgericht_ther_startdat1 | Start date of first tumour-directed therapy
+
Available from 2011. In the period 2005-2010, mainly available if a resection was performed.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | tumgericht_ther | Tumour-directed therapy performed
+
One or more treatments aimed at removing, destroying or reducing the primary tumour and/or metastases. Supportive or preparatory treatments only (such as biliary drainage, embolisation, etc.), exploratory surgery without resection, or cases where treatment is unknown are classified as no tumour-directed therapy performed.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | tumgericht_ther_zkh1 | Hospital of first tumour-directed therapy |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | voedselpassage | Stent or feeding stoma placed to improve food passage
+
Available since 2015.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | voedselpassage_dat[1-2] | Date of procedure to improve food passage[1-2]
+
Available since 2015.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | voedselpassage_int[1-2] | Interval incidence date and date of procedure to improve food passage (days)[1-2]
+
Available since 2015.
The incidence date is the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | voedselpassage_type[1-2] | Type of procedure to improve food passage[1-2]
+
Available since 2015.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | voedselpassage_zkh[1-2] | Hospital where a procedure to improve food passage was performed[1-2] |
valuelist
+
|